Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERGOLOID MESYLATES vs ERGOSTAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.
Treatment of age-related cognitive decline,Dementia (unlabeled use)
FDA-approved: Acute treatment of migraine headache with or without aura,Off-label: Cluster headache, vascular headache
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Terminal half-life is 2–3 hours (intravenous) and 2–4 hours (oral). Short half-life necessitates frequent dosing; duration of action limited to 2–4 hours.
Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect.
Primarily hepatic via CYP3A4. Undergoes extensive first-pass metabolism.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Primarily hepatic (biliary-fecal) elimination: ~90% of a dose is excreted in feces as metabolites; renal excretion accounts for <5% unchanged drug.
Approximately 90% bound to albumin.
~65% bound to plasma albumin. Metabolites are less extensively bound.
1.5-2 L/kg, indicating extensive tissue distribution.
Approximately 0.2–0.3 L/kg, indicating primarily extracellular and peripheral tissue distribution with limited CNS penetration.
Oral: less than 10% due to extensive first-pass metabolism.
Oral: ~10–20% (extensive first-pass metabolism); Sublingual: ~50–60% (avoids portal circulation); Rectal: ~30–40% (variable).
Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 m L/min).
No specific adjustment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Not established; safety and efficacy not determined in pediatric patients.
Intravenous: 0.1 mg/m² body surface area every 2-4 hours, maximum 0.5 mg total; intramuscular: 0.2 mg every 2-4 hours, maximum 1 mg.
Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects.
Start at 0.1 mg intramuscularly or intravenously; monitor for hypertension with higher doses.
No FDA black box warning.
Concomitant use with strong CYP3A4 inhibitors (e.g., protease inhibitors, macrolide antibiotics, azole antifungals) can lead to serious and/or life-threatening peripheral ischemia and vasospasm. Avoid coadministration.
Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism.
Risk of ischemia (peripheral, cerebral, coronary) especially with prolonged use or overdose,Fibrotic complications (cardiac valvulopathy, pulmonary, retroperitoneal fibrosis) with chronic use,Medication overuse headache (MOH) with frequent use, Avoid in patients with uncontrolled hypertension, coronary artery disease, or peripheral vascular disease,Do not exceed recommended dosage; may cause ergotism
Hypersensitivity to ergot alkaloids; severe hypotension; acute or chronic psychosis; concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals).
Concurrent use of potent CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, ketoconazole, ritonavir)
Avoid grapefruit juice as it may increase drug levels. Limit caffeine intake as it may exacerbate vasoconstrictive effects. Maintain adequate hydration.
Avoid grapefruit juice as it may increase ergonovine levels. No other significant food interactions.
Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions.
Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified as FDA Pregnancy Category X. Use in the first trimester may increase the risk of spontaneous abortion; in the second and third trimesters, it can precipitate preterm labor and fetal distress. There is no evidence of structural teratogenicity from direct drug effects, but the potential for ischemic injury to the fetus due to uterine hyperstimulation exists.
Excreted into breast milk; M/P ratio unknown. May suppress prolactin and reduce milk production. Potential for ergotism in neonates (vomiting, diarrhea, convulsions). Contraindicated during breastfeeding.
Ergonovine is excreted into breast milk. The M/P ratio is not well established, but small amounts are detectable. It may cause adverse effects in the nursing infant, including vomiting, diarrhea, and transient hypertension. Because of the risk of ergotism in the infant, breastfeeding is generally not recommended during therapy. A decision should be made to discontinue breastfeeding or discontinue the drug, considering the importance of the drug to the mother.
No established safe dose in pregnancy. Avoid use. If absolutely necessary, lowest effective dose and shortest duration, but no specific pharmacokinetic data available to guide adjustments.
No dosing adjustments are recommended or studied because use in pregnancy is contraindicated. If exposure occurs accidentally or for life-threatening indications (e.g., severe postpartum hemorrhage), the same doses used in non-pregnant adults (0.2 mg IM or IV) may be employed, but with extreme caution due to heightened sensitivity to uterotonic effects. No pharmacokinetic studies in pregnancy exist; however, increased plasma volume and altered hepatic metabolism may require careful titration, but no specific evidence supports dose changes.
Ergoloid mesylates are a mixture of dihydrogenated ergot alkaloids historically used for dementia, though efficacy is unproven. Avoid in patients with psychosis, severe bradycardia, or recent MI. Monitor for ergotism symptoms (vasospasm, ischemia). Not recommended due to lack of evidence.
ERGOSTAT (ergonovine) is an ergot alkaloid used for postpartum hemorrhage. It causes sustained uterine contraction. Contraindicated in hypertension, preeclampsia, and vascular disease. Administer IM or IV slowly over 1 minute to avoid severe vasoconstriction. Monitor blood pressure and uterine tone closely. Do not use in patients with hypersensitivity to ergot alkaloids.
Take exactly as prescribed; do not double doses if missed.,Report signs of ergotism: cold/blue fingers/toes, muscle pain, tingling or numbness.,Avoid smoking and caffeine as they may worsen vasoconstriction.,May cause dizziness or fainting; avoid driving until you know how the drug affects you.,Do not use with other ergot alkaloids or triptans.
This medication is given to control bleeding after childbirth.,It may cause nausea, vomiting, or dizziness.,Report severe headache, chest pain, or vision changes immediately.,Avoid smoking or using nicotine products while on this drug.,Do not breastfeed within 12 hours after the last dose; discuss with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERGOLOID MESYLATES vs ERGOSTAT, answered by our medical review team.
ERGOLOID MESYLATES is a Ergot Alkaloid that works by Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.. ERGOSTAT is a Ergot Alkaloid Antimigraine that works by Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERGOLOID MESYLATES and ERGOSTAT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERGOLOID MESYLATES is: Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.. The standard adult dose of ERGOSTAT is: 0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERGOLOID MESYLATES and ERGOSTAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERGOLOID MESYLATES is classified as Category A/B. Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. . ERGOSTAT is classified as Category C. Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.